annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 50E The development and implementation of an institution-based communication
skills training program for oncologists. (Abstract #9128)
P. A. Bialer, T. Gilewski, D. Kissane, T. Levin, M. N. Dickler, B. J. Park, C. Bylund
Brd. 50F Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with
topical menthol: A phase I study. (Abstract #9129)
D. J. Storey, L. A. Colvin, A. C. Scott, D. Boyle, L. Green, A. P. Jones, M. T. Fallon
Brd. 50G Activation of the MAP-kinase pathway in the skin of patients treated with
sorafenib: Clinical and molecular characterization of skin tumors associated
with the multikinase inhibitor sorafenib. (Abstract #9130)
C. Mateus, J. Arnault, G. Tomasic, E. Hollville, L. Lacroix, J. Wechsler,
B. J. Escudier, A. Eychene, J. Soria, C. Robert
Brd. 50H Quality of life (QOL) and cognitive performance among irradiated brain
cancer patients. (Abstract #9131)
M. J. Naughton, L. D. Case, C. A. Meyers, M. E. Loghin, E. G. Shaw,
T. J. Saphner, B. G. Sleckman, J. K. Giguere, G. J. Lesser, S. R. Rapp
Brd. 51A The impact of pharmacotherapy on depression and quality of life in patients
undergoing a bone marrow transplant (BMT). (Abstract #9132)
P. B. Mumby, C. Garcia, R. Trivedi-Purohit, R. Gourvitz, K. Rychlik, T. Rodriguez,
S. E. Smith, A. A. Toor, M. Rao, P. J. Stiff, BMT Program
Brd. 51B Delaying skeletal-related events in a randomized phase III study of
denosumab versus zoledronic acid in patients with advanced cancer.
(Abstract #9133)
D. H. Henry, R. von Moos, V. Hungria, L. Costa, P. J. Woll, G. Scagliotti, J. Wang,
S. Jun, R. D. Dansey, H. Yeh
Brd. 51C Prevalence of memory problems that limit daily functioning in adult cancer
patients: A national representative sample of the U.S. population.
(Abstract #9134)
P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo,
S. E. Lipshultz, T. L. Miller, G. R. Morrow, K. Fiscella
Brd. 51D Natural history of paclitaxel-associated acute pain syndrome (P-APS):
NCCTG trial N08C1. (Abstract #9135)
B. Reeves, S. R. Dakhil, J. A. Sloan, A. Kamal, S. L. Wolf, K. N. Burger,
N. LeLindqwister, G. S. Soori, A. J. Jaslowski, C. L. Loprinzi
Brd. 51E Effect of bevacizumab on the risk of chemotherapy-associated anemia in
cancer patients: A meta-analysis. (Abstract #9136)
A. F. Sher, S. Wu
Brd. 51F Prevalence of lymphedema and upper-limb impairments after axillary lymph
node dissection or sentinel lymph node dissection in breast cancer: A
two-year follow-up study. (Abstract #9137)
A. Sagen, R. Kåresen, M. J. Hjermstad, M. Risberg, Oslo University Hospital
Brd. 51G Effect of timing of information on exercise on exercise behavior during
cancer treatment: A URCC CCOP protocol. (Abstract #9138)
L. Sprod, L. J. Peppone, O. Palesh, M. C. Janelsins, C. E. Heckler, L. K. Colman,
J. J. Kirshner, P. W. Bushunow, G. R. Morrow, K. M. Mustian
Brd. 51H Gabapentin for the management of hot flashes in prostate cancer survivors:
A longitudinal continuation study—NCCTG trial N00CB. (Abstract #9139)
A. R. Moraska, P. J. Atherton, D. W. Szydlo, D. L. Barton, P. J. Stella,
K. M. Rowland, P. L. Schaefer, J. E. Krook, J. Bearden, C. L. Loprinzi
Brd. 52A Testosterone levels and quality of life (QoL) in male patients with hormoneindependent
cancers (HIC). (Abstract #9140)
S. B. Fleishman, H. Khan, M. J. Guarino, M. Suhail, R. A. Strebel, P. Homel,
V. Rosenwald, T. Mirzoyev, T. F. Wozniak, K. Suppiah
Brd. 52B Overall survival in randomized controlled trials of chemotherapy (CT) with or
without GCSF support: A systematic review. (Abstract #9141)
G. H. Lyman, D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff,
N. M. Kuderer, J. Crawford
384